Cardiovascular responses to an isosterically modified prostaglandin analog in conscious dogs

The cardiovascular effects of oral and intravenous administration of 0.05 and 0.1 mg/kg of the isosterically modified prostaglandin (PG) analog, (+)-4-{3-3-2-(1-hydroxycyclohexyl)ethyl]-4-oxo-thiazolidinyl]propy} benzoic acid were ascertained in conscious mongrels. After 0.05 mg/kg p.o., mean arterial pressure (MAP), obtained from indwelling catheters, fell from 105 ± 1 to 100 ± 4 mm Hg and total peripheral resistance (TPR) decreased from 0.062 ± 0.006 to 0.039 ± 0.002 mm Hg/ml/min. Cardiac output (CO), measured via electromagnetic flow probes, rose from 1.8 ± 0.2 to 2.6 ± 0.1 l/ml and heart rate from 109 ± 13 to 128 ± 8 beats/min. The 0.1 mg/kg p.o. dose produced similar results. Intravenous injection of 0.1 mg/kg immediately dropped MAP from 103 ± 6 to 58 ± 3 mm Hg and TRP from 0.049 ± .006 to .014 ± .002 mm Hg/ml/min. CO climbed from 2.3 ± 0.2 to 0.2 to 5.3 ± 0.5 l/ml and HR increased from 126 ± 9 to 254 ± 14 beats/min. Stroke volume was not affected by either oral or intravenous administration of the PG analog. Pretreatment with 100 μg/kg timolol blunted the CO and HR responses to 0.1 mg/kg iv of the PG analog without affecting the depressor response. Metaramidol infused during injection of 0.1 mg/kg iv of the PG analog diminished all responses. When compared to the cardiovascular effects of hydralazine and nitroprusside, the profile of the PG analog activity closely resembled that produced by the arterial vasodilator, hydralazine; in contrast, nitroprusside (which also dilates veins) reduced stroke volume, but did not significantly affect HR. In conclusion, dilation of the resistance vessels by the PG analog decreased MAP and TPR and reflexly elevated CO and HR in conscious dogs.